Nevro (NYSE:NVRO) announced today that it received CE mark in Europe for its HFX iQ spinal cord stimulation (SCS) system.

Realizing a Phase I human clinical trial commencing to test the efficacy and safety of the transplantation of olfactory cell nerve bridges to treat chronic spinal cord injury. Since the passing of ...

Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.

A $2.5 million federal grant will fund a four-year study led by Kessler Foundation scientist Karen J. Nolan, PhD, to explore ...

Utilizing the Dural Substitute Confetti technique during spinal cord stimulation trial implantation may reduce complications and shorten surgery time.

A team of researchers led by Rice University's Jacob Robinson and the University of Texas Medical Branch's Peter Kan has ...

Australian researchers are about to launch a human trial to treat spinal cord injury by transplanting cells from the noses of paralysed patients into the damaged area. Griffith University ...

By implanting electrodes in the brain and spinal cord to build a "nerve bypass" system between the two body parts, scientists from Fudan University in Shanghai have reached a breakthrough in ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...